Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (14081)	7/11/2000 8:06:47 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Lilly's rhAPC definitely safer, cheaper and purer to produce than the bax plasma way even if the bax gets it as a by product of their other plasma business (difficult cause they can not removed it from whole blod or fresh frozen plasma and still claim it is whole blood or fresh froxen plasma as one would with immnunoglobulins). Very doubfult that bax will get it trough. As for the other rhAPC properties is reasonable but more work is needed, but with recent TPA poor results and risks in market conditions for stroke this seems a logical next step. Correction: Sepsis shock market is 500,000 patients (not 50,000)if it works in severe trauma (like Icos drug)is another 0.5 to 1 million.